Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by Johnandrose22 on Feb 23, 2023 7:13am

Ruvidar

If the company has just announced a brand name for TLD 1433, are they also indicating that BTD/AA is almost here?

Welcome Ruvidar!
Comment by toade1313 on Feb 23, 2023 7:36am
That's  Radivur backwards.  Now the $.38 (backwards) will be $.83..
Comment by blackjack0 on Feb 23, 2023 8:36am
Ruvidar bring it on!
Comment by Lesalpes29 on Feb 23, 2023 8:39am
Happy to see the name. An other piece in place. GL
Comment by Legit62 on Feb 23, 2023 8:45am
BTD and AA will be in rearview mirror soon!!! Congrats longs
Comment by charlierock on Feb 23, 2023 9:08am
I like the name RUVIDAR " the gift of life" kinda catchy and Dr. Mandel's statement was encouraging, " one day we hope that RUVIDAR will become the organ-sparing solution that is a GAME - CHANGER for both patients and physicians "
Comment by jicoop on Feb 23, 2023 9:08am
Like naming an unborn child, only when birth is viable and imminent . sorry if this post offends anybody. Coop
Comment by StevenBirch on Feb 23, 2023 9:32am
I look forward to the day when every time you turn on the TV there is one of those annoying commercials for ... Ruvidar. Minus the laundry list of side effects though.
Comment by Rumpl3StiltSkin on Feb 23, 2023 9:35am
It does roll off the tongue nicely, will probably be a household name soon. I am very very impressed! :-)
Comment by jicoop on Feb 23, 2023 9:36am
agree, every commercial I see now is either Ozempic or on-line gambling sites ! Coop
Comment by Eoganacht on Feb 23, 2023 11:16am
One day you'll be able to spot an oldtimer when you hear them say TLD1433 instead of Ruvidar! Does this qualify as the beginning of the "Commercialization Phase" slated for the first quarter of 2023 in the projected timeline of the Corporate Presentation?
Comment by StevenBirch on Feb 23, 2023 11:44am
Nice thought Eog, looks like we have moved past just waiting for the next round of results. No matter how good they never moved the stock anyway, we have bigger fish to fry now with BTD, AA then additional trials for NSCLC and GBM. Every one of those should impact the price.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250